Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech/Curis To Reformulate Basal Cell Carcinoma Topical Treatment

This article was originally published in The Pink Sheet Daily

Executive Summary

Preliminary Phase I results show histological clearance, but less clinical activity than anticipated with Hedgehog antagonist, Curis says.

You may also be interested in...

Curis To Continue Focus On Oncology After Wyeth Ends Hedgehog Venture

Cambridge, Mass.-based Curis seeks a new partner to continue small molecule and protein hedgehog agonist development in cardiovascular/nervous system disorders.

Tarceva Pancreatic Cancer Indication Turned Down In The EU

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts